https://clinicaltrials.gov/ct2/show/NCT04509791?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F29%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
DESCRIPTION:
Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Sponsor: Universitaire Ziekenhuizen Leuven
Not yet recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT04509791
FIRST POSTED:
Wed, 12 Aug 2020 12:00:00 EDT
LAST UPDATE POSTED:
08/12/20 07:22AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04509791?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F29%2F2020&lupd_d=14&sort=nwst
